Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

Authors
Park, Yeon HeeKim, Tae YongIm, Young-HyuckLee, Keun-SeokPark, In HaeSohn, JoohyukLee, Soo-HyeonIm, Seock-AhKim, Jee HyunKim, Se HyunLee, Soo JungKoh, Su-JinLee, Ki HyeongChoi, Yoon JiCho, Eun KyungLee, SueeKang, Seok YunSeo, Jae HongKim, Sung-BaeJung, Kyung Hae
Issue Date
4월-2017
Publisher
KOREAN CANCER ASSOCIATION
Keywords
Eribulin; Breast neoplasms; Metastasis; Safety; Phase IV clinical trial; Korean
Citation
CANCER RESEARCH AND TREATMENT, v.49, no.2, pp.423 - 429
Indexed
SCIE
SCOPUS
KCI
Journal Title
CANCER RESEARCH AND TREATMENT
Volume
49
Number
2
Start Page
423
End Page
429
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/83948
DOI
10.4143/crt.2016.191
ISSN
1598-2998
Abstract
Purpose Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials. Materials and Methods In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m(2) dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease. Results A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively. Conclusion This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Seo, Jae Hong photo

Seo, Jae Hong
의과학과
Read more

Altmetrics

Total Views & Downloads

BROWSE